ImClone names new CEO

ImClone, the maker of Erbitux, has named John H. Johnson its CEO, effective August 27, 2007. Johnson was previously Johnson & Johnson's Company Group Chairman of Worldwide Biopharmaceuticals. The top spot at ImClone has been vacant since billionaire investor Carl Icahn took the helm as the former CEO Joseph Fischer bowed out. ImClone's only approved drug--Erbitux--recently flunked a Phase III lung cancer trial and faces competition from other cancer drugs.

- see this press release for more

Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.